COVID-19: Implications for Patients With CLL

Keep abreast of ongoing developments in providing optimal care for patients with CLL during COVID-19 and evolving research into countering COVID-19–associated inflammatory cytokine production! Get expert perspectives on emerging data with focused commentaries, an FAQ module, and a “living” slideset regularly updated to incorporate the most important clinical findings on CLL and COVID-19.
Jacqueline Barrientos, MD, MS
Brian Koffman, MDCM (retired), MS Ed
Nicole Lamanna, MD
John Pagel Headshot
John Pagel, MD, PhD
Jeff P. Sharman, MD

ClinicalThought

What conclusions can we draw from these preliminary data for the use of BTK inhibitors to treat the hyperinflammatory immune response in patients with severe COVID-19?

Jeff P. Sharman, MD Released: June 16, 2020

How are you using telemedicine or other strategies to manage your patients with CLL during the COVID-19 pandemic?

John Pagel Headshot John Pagel, MD, PhD Released: July 13, 2020

How are you managing your patients with CLL during the COVID-19 pandemic? Here, I share my experiences during the height of the pandemic in New York City and offer recommendations to minimize the risk to your patients.

Jacqueline Barrientos, MD, MS Released: August 11, 2020

As a physician and CLL survivor, I share insights on the patient’s experience in the ongoing COVID-19 pandemic plus recommendations for counseling patients with CLL on how best to protect their physical and mental health.

Brian Koffman, MDCM (retired), MS Ed Released: August 31, 2020

Our understanding of how COVID-19 affects our patients with CLL continues to evolve. Here, I share my perspective on treatment modifications during the pandemic, using IVIg as COVID-19 prophylaxis, the role of BTK inhibition, and counseling patients on COVID-19 risk.

Nicole Lamanna, MD Released: September 14, 2020
Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
AstraZeneca

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?